Journal Article

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Gasparetto, Cristina, Basu, Cynthia, Dholaria, Bhagirathbhai, Jakubowiak, Andrzej, Lesokhin, Alexander M., Solh, Melhem, Chan, Edward M., Raje, Noopur S., Chu, Michael P., Skoura, Athanasia, Dalovisio, Andrew, Trudel, Suzanne, Tomasson, Michael H., Costello, Caitlin L., Levy, Moshe Y., Sebag, Michael, Damore, Michael A., Jiang, Sibo, Bahlis, Nizar J.

2023

Overview

Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-limiting toxicities as well as objective response rate (ORR) and duration of response (DOR), were met. Secondary efficacy endpoints included progression-free survival (PFS) and overall survival (OS). Eighty-eight patients with relapsed or refractory MM received elranatamab monotherapy, and 55 patients received elranatamab at efficacious doses. Patients had received a median of five prior regimens; 90.9% were triple-class refractory, 29.1% had high cytogenetic risk and 23.6% received prior BCMA-directed therapy. No dose-limiting toxicities were observed during dose escalation. Adverse events included cytopenias and cytokine release syndrome. Exposure was dose proportional. With a median follow-up of 12.0 months, the ORR was 63.6% and 38.2% of patients achieving complete response or better. For responders, the median DOR was 17.1 months. All 13 patients evaluable for minimal residual disease achieved negativity. Even after prior BCMA-directed therapy, 53.8% achieved response. For all 55 patients, median PFS was 11.8 months, and median OS was 21.2 months. Elranatamab achieved durable responses, manageable safety and promising survival for patients with MM. ClinicalTrials.gov Identifier: NCT03269136 . In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 692/699/1541/1990/804 / 692/699/67/1990/804 / Anemia - etiology / Antibodies / Antigens / B-Cell Maturation Antigen / Biomedical and Life Sciences / Biomedicine / Bispecific antibodies / Cancer Research / CD3 antigen / Constraining / Cytogenetics / Effectiveness / Humans / Immunotherapy, Adoptive - adverse effects / Infectious Diseases / Lymphocytes / Lymphocytes T / Malignancy / Metabolic Diseases / Minimal residual disease / Molecular Medicine / Multiple myeloma / Multiple Myeloma - pathology / Neurosciences / Pharmacokinetics / Progression-Free Survival / Safety management / Survival / T-Lymphocytes - pathology / Toxicity